MicroRNA Biomarkers for Coronary Artery Disease?
Dorothee KaudewitzAnna ZampetakiManuel MayrPublished in: Current atherosclerosis reports (2016)
MicroRNA (miRNA, miR) measurements in patients with coronary heart disease are hampered by the confounding effects of medication commonly used in cardiovascular patients such as statins, antiplatelet drugs, and heparin administration. Statins reduce the circulating levels of liver-derived miR-122. Antiplatelet medication attenuates the release of platelet-derived miRNAs. Heparin inhibits the polymerase chain reactions, in particular the amplification of the exogenous Caenorhabditis elegans spike-in control, thereby resulting in an artefactual rise of endogenous miRNAs. As these limitations have not been previously recognised, a reevaluation of the current miRNA literature, in particular of case-control studies in patients with cardiovascular disease or coronary interventions, is required.
Keyphrases
- cardiovascular disease
- case control
- coronary artery disease
- cell proliferation
- long non coding rna
- end stage renal disease
- ejection fraction
- venous thromboembolism
- healthcare
- long noncoding rna
- systematic review
- chronic kidney disease
- newly diagnosed
- cardiovascular events
- coronary artery
- physical activity
- growth factor
- prognostic factors
- adverse drug
- aortic stenosis
- percutaneous coronary intervention
- peritoneal dialysis
- type diabetes
- coronary artery bypass grafting
- metabolic syndrome
- acute coronary syndrome
- transcatheter aortic valve replacement
- cardiovascular risk factors
- aortic valve
- label free